KIT and gastrointestinal stromal tumor: In patients with GIST treated with sunitinib, Deprimo et al. identified that a decreased level from baseline of soluble KIT in plasma was associated with increased time to progression, whilst Norden-Zfoni et al. showed that increased circulating endothelial cells upon treatment initiation was associated with improved outcomes [148,149].